Results 111 to 120 of about 3,178,268 (185)

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 - advanced breast cancer: a meta-analysis. [PDF]

Eur J Med Res
Danbala IA, Wang X, Su Y, Tang H, Sheng W, Shaibu Z, Isah I, Yuan X.   +7 more
europepmc   +1 more source

Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma. [PDF]

BMC Med Genomics, 2022
Mo C, Wu Y, Ma J, Xie L, Huang Y, Xu Y, Peng H, Chen Z, Zeng M, Mao R.   +9 more
europepmc   +1 more source

Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Stravodimou A, Voutsadakis IA.
europepmc   +1 more source

Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis. [PDF]

Rev Cardiovasc Med, 2023
Liu YS, Dong K, Park C.
europepmc   +1 more source

Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. [PDF]

Sci Rep, 2023
Ford K, Munson BP, Fong SH, Panwala R, Chu WK, Rainaldi J, Plongthongkum N, Arunachalam V, Kostrowicki J, Meluzzi D, Kreisberg JF, Jensen-Pergakes K, VanArsdale T, Paul T, Tamayo P, Zhang K, Bienkowska J, Mali P, Ideker T.   +18 more
europepmc   +1 more source

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis. [PDF]

J Pharm Policy Pract
Elazzazy S, Hisham Al-Ziftawi N, Shafei L, Mohamed Ibrahim MI, Bojassoum S, Hamad A.   +5 more
europepmc   +1 more source

Targeting CDK4 and CDK6 in cancer. [PDF]

Nat Rev Cancer, 2022
Goel S, Bergholz JS, Zhao JJ.
europepmc   +1 more source

Knockout of cyclin-dependent kinases 8 and 19 leads to depletion of cyclin C and suppresses spermatogenesis and male fertility in mice. [PDF]

Elife
Bruter AV, Varlamova EA, Stavskaya NI, Antysheva ZG, Manskikh VN, Tvorogova AV, Korshunova DS, Khamidullina AI, Utkina MV, Bogdanov VP, Baikova IP, Nikiforova AI, Albert EA, Maksimov DO, Li J, Chen M, Schools GP, Feoktistov AV, Shtil AA, Roninson IB, Mogila VA, Silaeva YY, Tatarskiy VV.   +22 more
europepmc   +1 more source

Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy. [PDF]

Oncologist
Jacobs F, Gaudio M, Andreottola C, Borroni R, Benvenuti C, Saltalamacchia G, Gerosa R, Canzian J, Tiberio P, Torrisi R, Masci G, Miggiano C, Zambelli A, Santoro A, De Sanctis R.   +14 more
europepmc   +1 more source

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review. [PDF]

J Zhejiang Univ Sci B
Zheng S, Chen Y, Zhu Z, Li N, He C, Koeffler HP, Han X, Wei Q, Xu L.   +8 more
europepmc   +1 more source